subscribeSubscribe
U.S. FDA declines to approve Cytokinetics` heart drug

U.S. FDA declines to approve Cytokinetics` heart drug
REUTERS
01 Mar 2023
Share Share
Cytokinetics` heart drug fails to secure FDA panel`s support

Cytokinetics` heart drug fails to secure FDA panel`s support
Pratik Jain REUTERS
14 Dec 2022
Share Share
FDA staff reviewers flag safety concerns over Cytokinetics` heart drug

FDA staff reviewers flag safety concerns over Cytokinetics` heart drug
REUTERS
10 Dec 2022
Share Share
Cytokinetics Announces Availability of Documents for FDA Meeting on Omecamtiv Mecarbil

Cytokinetics Announces Availability of Documents for FDA Meeting on Omecamtiv Mecarbil
GLOBENEWSWIRE
09 Dec 2022
Share Share
Cytokinetics Announces Date for FDA Meeting to Review NDA for Omecamtiv Mecarbil

Cytokinetics Announces Date for FDA Meeting to Review NDA for Omecamtiv Mecarbil
GLOBENEWSWIRE
24 Jun 2022
Share Share
Cytokinetics Provides Regulatory Update Related to NDA for Omecamtiv Mecarbil

Cytokinetics Provides Regulatory Update Related to NDA for Omecamtiv Mecarbil
GLOBENEWSWIRE
17 May 2022
Share Share
Cytokinetics` heart drug fails a phase 3 as it awaits FDA nod

Cytokinetics` heart drug fails a phase 3 as it awaits FDA nod
Kyle LaHucik FIERCEBIOTECH
16 Feb 2022
Share Share
Cytokinetics Announces FDA Acceptance of NDA for Omecamtiv Mecarbil

Cytokinetics Announces FDA Acceptance of NDA for Omecamtiv Mecarbil
GLOBENEWSWIRE
04 Feb 2022
Share Share
Cytokinetics, Royalty partner on heart failure drug for $450M

Cytokinetics, Royalty partner on heart failure drug for $450M
N. DeFeudis ENDPTS
08 Jan 2022
Share Share
Cytokinetics and JI XING Announce Expansion of Collab to Include Licensing

Cytokinetics and JI XING Announce Expansion of Collab to Include Licensing
GLOBENEWSWIRE
20 Dec 2021
Share Share